Gayathri Kallukaran is a Junior Journalist with Eastern Eye. She has a Master’s degree in Journalism and Mass Communication from St. Paul’s College, Bengaluru, and brings over five years of experience in content creation, including two years in digital journalism. She covers stories across culture, lifestyle, travel, health, and technology, with a creative yet fact-driven approach to reporting. Known for her sensitivity towards human interest narratives, Gayathri’s storytelling often aims to inform, inspire, and empower. Her journey began as a layout designer and reporter for her college’s daily newsletter, where she also contributed short films and editorial features. Since then, she has worked with platforms like FWD Media, Pepper Content, and Petrons.com, where several of her interviews and features have gained spotlight recognition. Fluent in English, Malayalam, Tamil, and Hindi, she writes in English and Malayalam, continuing to explore inclusive, people-focused storytelling in the digital space.
Covid-19 infections are seeing a mild resurgence in parts of South Asia, with India reporting more than 1,000 active cases as of 26 May 2025. While overall numbers remain significantly lower than during previous waves, health authorities across the region have urged caution as new variants have been identified and localised outbreaks persist.
In India, the Ministry of Health confirmed 1,009 active cases across the country, marking a steady rise in recent weeks. The states of Kerala, Maharashtra, and Delhi are currently among the worst affected. Delhi alone has crossed the 100-case mark, with urban centres in southern and western India also experiencing a gradual increase.
Health officials in India are particularly concerned about the emergence of two new Covid-19 variants. A case of the NB.1.8.1 variant was identified in Tamil Nadu in April, while four cases of the LF.7 variant were reported in Gujarat earlier in May. Both variants are being closely monitored by researchers to determine their potential impact, with preliminary studies suggesting the need for vigilance but no immediate cause for alarm.
Authorities in Nagpur, Bengaluru, Andhra Pradesh, Telangana, and Kerala have reported localised increases in Covid-19-related illnesses. Although the majority of new infections remain mild or asymptomatic, hospitals have been advised to maintain readiness for any future escalation.
In Bangladesh, the most recent publicly available data dates back to July 2023, when the country reported around 2.05 million total cases and 29,477 deaths since the beginning of the pandemic. At the time, the number of active cases stood at 18,331, but no significant updates have been issued by Bangladeshi health authorities in 2024 or 2025.
Nepal last reported Covid-19 data in May 2023, with over 1 million confirmed infections and 12,031 deaths. The number of active cases at that time was 28, and no official updates have been released since. The low count may reflect a combination of reduced testing and minimal public health reporting, rather than a complete absence of cases.
In Sri Lanka, data from July 2023 indicated 672,729 total cases and 16,893 deaths, with just eight active cases recorded. The Sri Lankan government has not provided any newer figures, and the situation appears stable, though the absence of updates makes current conditions difficult to assess accurately.
Pakistan's National Institute of Health (NIH) responded in January 2025 to online speculation about a new Covid-19 surge, stating that there was no significant rise in infections. The agency confirmed that the situation remained under control, and no new health advisories have been issued since.
Across the region, testing rates remain much lower than during earlier phases of the pandemic, making it difficult to get a complete picture of the current transmission levels. However, health experts have warned that complacency could prove costly if a more transmissible or immune-evasive variant emerges.
While the World Health Organisation has not issued any updated guidance specific to South Asia in recent weeks, it continues to recommend vaccinations, especially booster doses for vulnerable populations. Many countries in the region have moved to an endemic phase in their pandemic response, with Covid-19 management integrated into general healthcare systems.
For UK residents with family ties or travel plans in South Asia, the recent trends may be a reminder to stay informed and exercise caution. Travellers are encouraged to check the latest government travel advice and ensure vaccinations are up to date before visiting the region.
Although current figures remain a fraction of the pandemic’s peak, the detection of new variants and the gradual rise in active cases suggest that Covid-19 has not disappeared. Public health officials continue to monitor developments closely, especially in densely populated urban areas where transmission could accelerate quickly.
As of now, there are no major travel restrictions or quarantine mandates in any South Asian country due to Covid-19. However, authorities have advised citizens, especially those with underlying health conditions, to practise basic hygiene measures and seek medical advice if symptoms emerge.
Key numbers (as of 26 May 2025):
India: 1,009 active cases; new variants NB.1.8.1 and LF.7 detected
Bangladesh: Last reported data (July 2023) – 2.05 million total cases, 18,331 active cases
Nepal: Last reported data (May 2023) – 1 million+ cases, 28 active cases
Sri Lanka: Last reported data (July 2023) – 672,729 total cases, 8 active cases
Pakistan: No rise in cases reported as of January 2025
With a fresh reminder that the virus continues to circulate, health experts advise staying informed and prepared, particularly in international settings.
A nurse walks through an alley at the Government Medical College, where children were admitted after consuming Coldrif cough syrup, which has been linked to the deaths of multiple children, in Nagpur, India, October 8, 2025.
INDIAN police have arrested the owner of a pharmaceutical company after a cough syrup made at his plant was linked to the deaths of at least 21 children, officials said on Thursday.
Most of the children, all under the age of five, died in Madhya Pradesh over the past month after being prescribed the syrup, which was found to be contaminated with a toxic substance.
Cough syrups manufactured in India have come under global scrutiny in recent years following deaths in several countries linked to their consumption. The incidents have affected India’s reputation as the world’s third-largest producer of drugs and pharmaceuticals by volume.
G. Ranganathan, 75, was arrested early on Thursday at his home in Chennai by police teams from Chennai and Madhya Pradesh.
He was charged with culpable homicide not amounting to murder and adulteration of drugs, police sources told AFP and Indian media reported.
The syrup, sold under the brand name Coldrif, was manufactured by Sresan Pharma at a unit in Tamil Nadu.
The Indian health ministry said on Saturday that tests on samples showed contamination with diethylene glycol (DEG), a toxic chemical used in industrial solvents that can be fatal even in small quantities.
Authorities in Madhya Pradesh and several other states have banned the product.
Indian media reported that the World Health Organization had asked Indian officials for clarification on whether the contaminated syrup had been exported to other countries.
In 2022, more than 70 children died in Gambia from acute kidney failure after consuming a cough syrup imported from India.
Between 2022 and 2023, 68 children in Uzbekistan died after consuming another contaminated syrup made in India.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.